Hot Stocks: Brokerage view on Exide, Divi’s Laboratories, Ashok Leyland & Sun TV

We have collated a list of recommendations from top brokerage firms from ETNow and other sources:

CLSA on Sun TV: Outperform| Target Rs 720
CLSA maintained an outperform rating on Sun TV but raised the target price to Rs 720 from Rs 675 earlier.

Data suggests that there is a jump in IPL revenues, but ad revenue declined in Q4. IPL revenue was up 130% on a YoY basis, but the core business ad revenue declines by about 3% on a YoY basis.

There are challenges in the core business, however, valuations look cheap and the stock offers 3% dividend yield.CLSA on Ashok Leyland: Buy| Target Rs 258
CLSA maintained a buy rating on Ashok Leyland post Q4 results but raised the target price to Rs 258 from Rs 238 earlier.Margin improved sequentially, which points to a strong pricing discipline. The CV industry outlook is strong for FY25. The management is bullish on the Electric CV segment.InCred on Divi’s Laboratories: Add | Target Rs 4707
InCred upgraded Divi’s Laboratories to Add from Reduce earlier and has also raised the target price to Rs 4707 from Rs 3333 earlier.

The Q4 performance beats expectations, and there is a substantial rise in enquiries in CCS business. There is substantial visibility improvement in the CCS business.

The global investment bank hikes FY25F/26F EPS by 12%/13%.

JPMorgan on Exide Industries: Overweight| Target Rs 520
JPMorgan maintained an overweight rating on Exide Industries post Q4 but raised the target price to Rs 520 from Rs 480 earlier.

The global investment bank believes that Exide is well positioned to deliver across all businesses.

The margins in the lithium-ion cell business is likely to be in the mid-teens at full capacity utilization.

Industrial demand (lead acid batteries) should not be underappreciated.

(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)